XML 59 R47.htm IDEA: XBRL DOCUMENT v3.26.1

Schedule of Contractual Clinical Trials (Details)	3 Months Ended
	Mar. 31, 2026 USD ($) Integer
Other Commitments [Line Items]
Remaining Financial Contractual Commitment | $	$ 293,000
Phase 1b [Member]
Other Commitments [Line Items]
Description of Clinical Trial	LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b)
Start Date	August 2024
Projected End Date	December 2026
Number of Patients in Trial | Integer	37
Expected Date of Preliminary Efficacy Signal	December 2027
Remaining Financial Contractual Commitment | $		[1]
Phase 1b Two [Member]
Other Commitments [Line Items]
Description of Clinical Trial	LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)
Start Date	June 2023
Projected End Date	Enrollment completed September 2024
Expected Date of Preliminary Efficacy Signal	March 2026
Remaining Financial Contractual Commitment | $	$ 293,000
Phase 1b Two [Member] | Minimum [Member]
Other Commitments [Line Items]
Number of Patients in Trial | Integer	9
Phase 1b Two [Member] | Maximum [Member]
Other Commitments [Line Items]
Number of Patients in Trial | Integer	18
Randomized Phase 2 [Member]
Other Commitments [Line Items]
Description of Clinical Trial	Doxorubicin with or without LB-100 in advanced soft tissue sarcoma (Randomized Phase 2)
Start Date	TBD
Projected End Date	TBD
Number of Patients in Trial | Integer	150
Expected Date of Preliminary Efficacy Signal	TBD
Remaining Financial Contractual Commitment | $		[1]
Phase 1b 2 [Member]
Other Commitments [Line Items]
Description of Clinical Trial	LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)
Start Date	January 2024
Projected End Date	December 2027
Number of Patients in Trial | Integer	42
Expected Date of Preliminary Efficacy Signal	December 2027
Remaining Financial Contractual Commitment | $		[1]
[1] The Company has no financial contractual commitments associated with these clinical trials at March 31, 2026.

X

- Definition

Clinical trial description.

+ References

No definition available.

+ Details

Name:	LIXT_ClinicalTrialDescription
Namespace Prefix:	LIXT_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Contractual clinical trial period end date

+ References

No definition available.

+ Details

Name:	LIXT_ContractualClinicalTrialPeriodEndDate
Namespace Prefix:	LIXT_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Contractual clinical trial period start date.

+ References

No definition available.

+ Details

Name:	LIXT_ContractualClinicalTrialPeriodStartDate
Namespace Prefix:	LIXT_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Expected date of preliminary efficacy signal.

+ References

No definition available.

+ Details

Name:	LIXT_ExpectedDateOfPreliminaryEfficacySignal
Namespace Prefix:	LIXT_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of patient in trial.

+ References

No definition available.

+ Details

Name:	LIXT_NumberOfPatientInTrial
Namespace Prefix:	LIXT_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialRandomizedPhaseTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: